Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

Rebecca Proudfoot; Bob Phillips; Sophie Wilne

doi:10.1097/MPH.0000000000000771

Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

Rebecca Proudfoot, Bob Phillips, Sophie Wilne

Centre for Reviews and Dissemination

Research output: Contribution to journal › Article › peer-review

Abstract

Although it is well-established that children undergoing allogeneic stem cell transplants and treatment for leukemia should be offered prophylaxis against Pneumocystis jirovecii pneumonia, the risk for children with solid malignancies is less certain. This guideline has been developed with the aim of standardizing practice and optimizing the benefit versus risk of prophylactic medication in this group of patients. P. jirovecii pneumonia has a high mortality rate even with prompt antimicrobial treatment. Since prophylaxis with co-trimoxazole is safe, effective, and inexpensive, we suggest that all children with malignancies undergoing immunosuppressive therapy are offered prophylaxis unless there are clear contraindications.

Original language	English
Journal	Journal of pediatric hematology/oncology
DOIs	https://doi.org/10.1097/MPH.0000000000000771
Publication status	Published - 6 Mar 2017

Bibliographical note

© 2017 Wolters Kluwer Health, Inc. All rights reserved. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

Keywords

Journal Article

Access to Document

10.1097/MPH.0000000000000771

PJP guideline final RHP06.07.2016
© 2017 Wolters Kluwer Health, Inc. All rights reserved. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
Accepted author manuscript, 338 KBLicence: Unspecified

Supportive care
Bob Phillips (Speaker)
15 Mar 2018
Activity: Talk or presentation › Invited talk

Cite this

@article{3698aa7717334947af2b9c4ad212efe7,

title = "Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors",

abstract = "Although it is well-established that children undergoing allogeneic stem cell transplants and treatment for leukemia should be offered prophylaxis against Pneumocystis jirovecii pneumonia, the risk for children with solid malignancies is less certain. This guideline has been developed with the aim of standardizing practice and optimizing the benefit versus risk of prophylactic medication in this group of patients. P. jirovecii pneumonia has a high mortality rate even with prompt antimicrobial treatment. Since prophylaxis with co-trimoxazole is safe, effective, and inexpensive, we suggest that all children with malignancies undergoing immunosuppressive therapy are offered prophylaxis unless there are clear contraindications.",

keywords = "Journal Article",

author = "Rebecca Proudfoot and Bob Phillips and Sophie Wilne",

note = "{\textcopyright} 2017 Wolters Kluwer Health, Inc. All rights reserved. This is an author-produced version of the published paper. Uploaded in accordance with the publisher{\textquoteright}s self-archiving policy. Further copying may not be permitted; contact the publisher for details.",

year = "2017",

month = mar,

day = "6",

doi = "10.1097/MPH.0000000000000771",

language = "English",

journal = "Journal of pediatric hematology/oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

AU - Proudfoot, Rebecca

AU - Phillips, Bob

AU - Wilne, Sophie

N1 - © 2017 Wolters Kluwer Health, Inc. All rights reserved. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

PY - 2017/3/6

Y1 - 2017/3/6

N2 - Although it is well-established that children undergoing allogeneic stem cell transplants and treatment for leukemia should be offered prophylaxis against Pneumocystis jirovecii pneumonia, the risk for children with solid malignancies is less certain. This guideline has been developed with the aim of standardizing practice and optimizing the benefit versus risk of prophylactic medication in this group of patients. P. jirovecii pneumonia has a high mortality rate even with prompt antimicrobial treatment. Since prophylaxis with co-trimoxazole is safe, effective, and inexpensive, we suggest that all children with malignancies undergoing immunosuppressive therapy are offered prophylaxis unless there are clear contraindications.

AB - Although it is well-established that children undergoing allogeneic stem cell transplants and treatment for leukemia should be offered prophylaxis against Pneumocystis jirovecii pneumonia, the risk for children with solid malignancies is less certain. This guideline has been developed with the aim of standardizing practice and optimizing the benefit versus risk of prophylactic medication in this group of patients. P. jirovecii pneumonia has a high mortality rate even with prompt antimicrobial treatment. Since prophylaxis with co-trimoxazole is safe, effective, and inexpensive, we suggest that all children with malignancies undergoing immunosuppressive therapy are offered prophylaxis unless there are clear contraindications.

KW - Journal Article

U2 - 10.1097/MPH.0000000000000771

DO - 10.1097/MPH.0000000000000771

M3 - Article

C2 - 28267082

SN - 1077-4114

JO - Journal of pediatric hematology/oncology

JF - Journal of pediatric hematology/oncology

ER -

Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors

Abstract

Bibliographical note

Keywords

Access to Document

Activities

Supportive care

Cite this